Standard BioTools (LAB) Expected to Announce Earnings on Wednesday

Standard BioTools (NASDAQ:LAB) is expected to be posting its quarterly earnings results after the market closes on Wednesday, February 26th. Analysts expect Standard BioTools to post earnings of ($0.03) per share and revenue of $43.03 million for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.

Standard BioTools Trading Down 0.7 %

Standard BioTools stock opened at $1.40 on Wednesday. Standard BioTools has a twelve month low of $1.17 and a twelve month high of $3.04. The stock’s fifty day simple moving average is $1.73 and its 200-day simple moving average is $1.82. The firm has a market capitalization of $521.16 million, a P/E ratio of -1.97 and a beta of 1.57.

Wall Street Analysts Forecast Growth

Separately, TD Cowen cut their price objective on Standard BioTools from $2.75 to $2.50 and set a “buy” rating on the stock in a research report on Thursday, October 31st.

About Standard BioTools

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.